Our study examined the immunity status and adverse events occurring after SARS-CoV-2 vaccination in a subgroup of individuals with multiple sclerosis who had previously contracted SARS-CoV-2 and were being treated with dimethyl fumarate and interferon beta. This evidence concerns the gene IFNB1 and multiple sclerosis.